Skip to main content

Table 3 Ongoing trials investigating the combination therapy of ICIs

From: Emerging treatment modalities for systemic therapy in hepatocellular carcinoma

Checkpoint inhibitors Phase Patients (No.) Clinical setting Status NCT numbers
Nivolumab + Ipilimumab I/II 32 Child-Pugh A HCC Recruiting NCT03682276
Nivolumab + Ipilimumab I 50 Unresectable HCC with Child Pugh Class A cirrhosis Active, not recruiting NCT03203304
Nivolumab + Ipilimumab II 30 HCC with potential surgical resection Active, not recruiting NCT03222076
Nivolumab + Ipilimumab III 650 Advanced HCC without prior systemic therapy Recruiting NCT04039607
Nivolumab + Ipilimumab II 40 HCC with potential for curative surgical resection Recruiting NCT03510871
Nivolumab + Mogamulizumab I 96 locally advanced or metastatic solid tumors Completed NCT02476123
Nivolumab + Relatlimab I 20 Potentially resectable HCC Not yet recruiting NCT04658147
Pembrolizumab + Bavituximab II 28 Locally advanced or metastatic HCC not amenable to locoregional therapy Recruiting NCT03519997
Durvalumab+ Tremelimumab III 1504 Unresectable HCC without prior systemic therapy Recruiting NCT03298451
Durvalumab+ Tremelimumab I 32 Unresectable, locally advanced liver cancer after radioembolization Suspended NCT04605731
Durvalumab+ Tremelimumab II 433 Advanced HCC Active, not recruiting NCT02519348